Современные возможности органосохраняющего лечения больных мышечно-инвазивным раком мочевого пузыря

Обложка

Цитировать

Полный текст

Аннотация

В статье представлен обзор современных направлений органосохраняющего лечения больных мышечно-инвазивным раком мочевого пузыря. Приведен исторический экскурс лечебной тактики при данном злокачественном заболевании. Продемонстрированы актуальные тенденции применения хирургических технологий, лучевой терапии, химио- и иммунопрепаратов, а также молекулярно-генетической диагностики у пациентов с инвазивными карциномами мочевого пузыря. Недостаток рандомизированных исследований не позволяет широко внедрить органосохраняющие методики в практику, но дает возможность использовать ее у тщательно отобранных групп пациентов.

Об авторах

Владимир Юрьевич Старцев

ФГБОУ ВО «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава России

Автор, ответственный за переписку.
Email: doc.urolog@gmail.com

д-р мед. наук, профессор кафедры онкологии, детской онкологии и лучевой терапии

Россия, Санкт-Петербург

Иван Николаевич Дыленок

ГБУЗ РК «Крымский республиканский онкологический клинический диспансер им. В.М. Ефетова»

Email: ivan_dylenok@mail.ru

заведующий отделением урологии

Россия, Симферополь

Тимур Рефатович Джемилев

ГБУЗ РК «Крымский республиканский онкологический клинический диспансер им. В.М. Ефетова»

Email: rumit_68@mail.ru

Urologist, Urological Department

Россия, Симферополь

Список литературы

  1. Gschwend JE, Fair WR, Vieweg J. Radical cystectomy for invasive bladder cancer: contemporary results and remaining controversies. Eur Urol. 2000;38(2):121-130. https://doi.org/10.1159/000020268.
  2. Khalil el SA. Long term complications following ileal conduit urinary diversion after radical cystectomy. J Egypt Natl Canc Inst. 2010;22(1):13-18.
  3. El-Taji OM, Khattak AQ, Hussain SA. Bladder reconstruction: The past, present and future. Oncol Lett. 2015;10(1):3-10. https://doi.org/10.3892/ol.2015.3161.
  4. Sauer R, Birkenhake S, Kühn R, et al. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys. 1998;40(1):121-127. https://doi.org/10.1016/s0360-3016(97)00579-8.
  5. Huddart RA, Hall E, Lewis R, et al. Life and death of spare (selective bladder preservation against radical excision): reflections on why the spare trial closed. BJU Int. 2010;106(6):753-755. https://doi.org/10.1111/j.1464-410X.2010.09537.x.
  6. Shipley W, Zietman A, Kaufman D, et al. Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates? The Massachusetts General Hospital and Radiation Therapy Oncology Group experiences. Semin Radiat Oncol. 2005;15(1):36-41. https://doi.org/10.1016/j.semradonc.2004.07.008.
  7. Arcangeli G, Strigari L, Arcangeli S. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials. Crit Rev Oncol Hematol. 2015;95(3):387-396. https://doi.org/10.1016/j.critrevonc.2015.04.006.
  8. Mak RH, Hunt D, Shipley WU, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014;32(34):3801-3809. https://doi.org/10.1200/JCO.2014.57.5548.
  9. El-Taji OM, Alam S, Hussain SA. Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers. Curr Treat Options Oncol. 2016;17(3):15. https://doi.org/10.1007/s11864-016-0390-8.
  10. nccn.org [Internet]. NCCN Clinical Practice Guidelines in Oncology [cited 1 Apr 2019]. Available from: www.nccn.org/professionals/physicians_gls.
  11. Witjes JA, Comperat E, Cowan NC, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65(4):778-792. https://doi.org/10.1016/j.eururo.2013.11.046.
  12. Jenkins BJ, Caulfield MJ, Fowler CG, et al. Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive (T2/T3) bladder cancer. Br J Urol. 1988;62(4):343-346. https://doi.org/10.1111/j.1464-410X.1988.tb04362.x
  13. Skinner EC. Treatment of muscle-invasive bladder cancer in older patients. Am Soc Clin Oncol Educ Book. 2016;35: e228-233. https://doi.org/10.14694/EDBK_158974.
  14. Koga F, Kihara K. Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review. Int J Urol. 2012;19(5):388-401. https://doi.org/10.1111/j.1442-2042.2012.02974.x.
  15. Walker M, French SD, Doiron RC, et al. Bladder-sparing radiotherapy for muscle-invasive bladder cancer: A survey of providers to determine barriers and enablers. Radiother Oncol. 2017;125(2):351-356. https://doi.org/10.1016/j.radonc.2017.08.036.
  16. Jensen TK, Jensen NV, Jorgensen SM, et al. Trends in cancer of the urinary bladder and urinary tract in elderly in Denmark, 2008-2012. Acta Oncol. 2016;55 Suppl 1:85-90. https://doi.org/10.3109/0284186X.2015.1115122.
  17. Poletajew S, Biernacki R, Buraczynski P, et al. Patterns of care in patients with muscle-invasive bladder cancer – a retrospective cohort study. Contemp Oncol (Pozn). 2016;20(4):341-343. https://doi.org/10.5114/wo.2016.61857.
  18. Clayman RH, Shipley WU, Galland-Girodet S, et al. Outcomes of selective bladder preservation in the elderly treated with conservative surgery and chemoradiation. Int J Radiat Oncol Biol Phys. 2013;87(2):S83. https://doi.org/10.1016/j.ijrobp.2013.06.216.
  19. Erlich A, Zlotta AR. Treatment of bladder cancer in the elderly. Investig Clin Urol. 2016;57 Suppl 1: S 26-35. https://doi.org/10.4111/icu.2016.57.S 1.S 26.
  20. Byun SJ, Kim JH, Oh YK, Kim BH. Concurrent chemoradiotherapy improves survival outcome in muscle-invasive bladder cancer. Radiat Oncol J. 2015;33(4):294-300. https://doi.org/10.3857/roj.2015.33.4.294.
  21. Grubmueller B, Seitz C, Shariat SF. The treatment of muscle-invasive bladder cancer in geriatric patients. Curr Opin Urol. 2016;26(2):160-164. https://doi.org/10.1097/MOU.0000000000000262.
  22. Lyons MD, Smith AB. Surgical bladder-preserving techniques in the management of muscle-invasive bladder cancer. Urol Oncol. 2016;34(6):262-270. https://doi.org/10.1016/j.urolonc.2015.11.023.
  23. Startsev VY. The role of combined method in organ-sparing treatment of muscle-invasive bladder cancer recurrences. Arch Ital Urol Androl. 2002;74(2):54-56.
  24. Solsona E, Iborra I, Collado A, et al. Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J Urol. 2010;184(2):475-480. https://doi.org/10.1016/j.juro.2010.04.008.
  25. Garcia MM, Gottschalk AR, Brajtbord J, et al. Endoscopic gold fiducial marker placement into the bladder wall to optimize radiotherapy targeting for bladder-preserving management of muscle-invasive bladder cancer: feasibility and initial outcomes. PLoS One. 2014;9(3):e89754. https://doi.org/10.1371/journal.pone.0089754.
  26. Abufaraj M, Gust K, Moschini M, et al. Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery. Transl Androl Urol. 2016;5(5):735-744. https://doi.org/10.21037/tau.2016.08.23.
  27. Moschini M, Luzzago S, Zaffuto E, et al. The surgical management of patients with clinical stage T4 bladder cancer: A single institution experience. Eur J Surg Oncol. 2017;43(4):808-814. https://doi.org/10.1016/j.ejso.2016.08.024.
  28. Riou O, Chauvet B, Lagrange JL, et al. [Radiotherapy of bladder cancer]. Cancer Radiother. 2016;20 Suppl:S 196-199. https://doi.org/10.1016/j.canrad.2016.07.010.
  29. Kibrom AZ, Knight KA. Adaptive radiation therapy for bladder cancer: a review of adaptive techniques used in clinical practice. J Med Radiat Sci. 2015;62(4):277-285. https://doi.org/10.1002/jmrs.129.
  30. Hafeez S, Warren-Oseni K, McNair HA, et al. Prospective study delivering simultaneous integrated high-dose tumor boost (≤70 Gy) with image guided adaptive radiation therapy for radical treatment of localized muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2016;94(5):1022-1030. https://doi.org/10.1016/j.ijrobp.2015.12.379.
  31. Lutkenhaus LJ, van Os RM, Bel A, Hulshof MC. Clinical results of conformal versus intensity-modulated radiotherapy using a focal simultaneous boost for muscle-invasive bladder cancer in elderly or medically unfit patients. Radiat Oncol. 2016;11:45. https://doi.org/10.1186/s13014-016-0618-6.
  32. Hoskin P, Rojas A, Saunders M. Accelerated radiotherapy, carbogen, and nicotinamide (ARCON) in the treatment of advanced bladder cancer: mature results of a Phase II nonrandomized study. Int J Radiat Oncol Biol Phys. 2009;73(5):1425-1431. https://doi.org/10.1016/j.ijrobp.2008.06.1950.
  33. Nowak-Sadzikowska J, Skora T, Szyszka-Charewicz B, Jakubowicz J. Muscle-invasive bladder cancer treated with TURB followed by concomitant boost with small reduction of radiotherapy field with or without of chemotherapy. Rep Pract Oncol Radiother. 2016;21(1):31-36. https://doi.org/10.1016/j.rpor.2015.09.001.
  34. Болотина Л.В., Королева Л.А. Современные подходы к лекарственной терапии рака мочевого пузыря после первого прогрессирования // Исследования и практика в медицине. – 2015. – Т. 2. – № 2. – С. 29–34. [Bolotina LV, Koroleva LA. Modern approaches to drug therapy of bladder cancer after first progression. Issledovaniya i praktika v meditsine. 2015;2(2):29-34. (In Russ.)]
  35. Rose TL, Milowsky MI. Improving Systemic Chemotherapy for Bladder Cancer. Curr Oncol Rep. 2016;18(5):27. https://doi.org/10.1007/s11912-016-0512-2.
  36. Pokuri VK, Syed JR, Yang Z, et al. Predictors of complete pathologic response (pT0) to neoadjuvant chemotherapy in muscle-invasive bladder carcinoma. Clin Genitourin Cancer. 2016;14(1): e59-65. https://doi.org/10.1016/j.clgc.2015.09.013.
  37. Font A, Taron M, Gago JL, et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol. 2011;22(1):139-144. https://doi.org/10.1093/annonc/mdq333.
  38. Guancial EA, Kilari D, Xiao GQ, et al. Platinum concentration and pathologic response to cisplatin-based neoadjuvant chemotherapy in muscle-invasive bladder cancer. PLoS One. 2016;11(5): e0155503. https://doi.org/10.1371/journal.pone.0155503.
  39. Plimack ER, Dunbrack RL, Brennan TA, et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol. 2015;68(6):959-967. https://doi.org/10.1016/j.eururo.2015.07.009.
  40. Xylinas E, Hassler MR, Zhuang D, et al. An epigenomic approach to improving response to neoadjuvant cisplatin chemotherapy in bladder cancer. Biomolecules. 2016;6(3). https://doi.org/10.3390/biom6030037.
  41. Sidaway P. Bladder cancer: Targeted agents reverse chemotherapy resistance in urothelial carcinoma. Nat Rev Urol. 2016;13(9):494. https://doi.org/10.1038/nrurol.2016.138.
  42. Sideris S, Aoun F, Zanaty M, et al. Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer. Mol Clin Oncol. 2016;4(6):1063-1067. https://doi.org/10.3892/mco.2016.821.
  43. Кулева С.А., Семиглазова Т.Ю., Звягинцева Д.А., и др. Cardiovascular complications of antineoplastic therapy in children // Педиатр. – 2017. – Т. 8. – № 3. – С. 130–141. [Kuleva SA, Semiglazova TY, Zvyagintseva DA, et al. Kardiovaskulyarnaya toksichnost’ protivoopukholevogo lecheniya u detey. Pediatrician (St. Petersburg). 2017;8(3):130-141. (In Russ.)]
  44. Raggi D, Miceli R, Sonpavde G, et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27(1):49-61. https://doi.org/10.1093/annonc/mdv509.
  45. Terashima Y. CDDP concentration of bladder tumors – comparison between intraarterial infusion and intravenous infusion. Nihon Gan Chiryo Gakkai Shi. 1988;23(4):859-866.
  46. Azuma H, Inamoto T, Takahara K, et al. Novel bladder preservation therapy with Osaka Medical College regimen. J Urol. 2015;193(2):443-450. https://doi.org/10.1016/j.juro.2014.08.094.
  47. Miyata Y, Nomata K, Ohba K, et al. Efficacy and safety of systemic chemotherapy and intra-arterial chemotherapy with/without radiotherapy for bladder preservation or as neo-adjuvant therapy in patients with muscle-invasive bladder cancer: a single-centre study of 163 patients. Eur J Surg Oncol. 2015;41(3):361-367. https://doi.org/10.1016/j.ejso.2014.07.043.
  48. Maebayashi T, Ishibashi N, Aizawa T, et al. Radiotherapy for muscle-invasive bladder cancer in very elderly patients. Anticancer Res. 2016;36(9):4763-4769. https://doi.org/10.21873/anticanres.11033.
  49. Тимофеев Д.А., Генералов М.И., Балахнин П.В., и др. Чрескожно имплантируемые инфузионные системы: расширение возможностей комбинированного лечения рака мочевого пузыря // Онкоурология. – 2009. – № 3. – С. 74–78. [Timofeev DA, Generalov MI, Balakhnin PV, et al. Transcutaneous infusion systems: extension of the capacities of multimodality treatment for urinary bladder cancer. Onkourologiya. 2009;(3):74-78. (In Russ.)]
  50. Горелов А.И., Симбирцев А.С., Журавский Д.А., Горелова А.А. Ингибиторы PD-1/PD-L1 в лечении рака мочевого пузыря: от медиатора иммунного ответа к таргетной терапии // Урологические ведомости. – 2018. – Т. 8. – № 2. – С. 64–72. [Gorelov AI, Simbirtsev AS, Zhuravskii DA, Gorelova AA. A review of the PD-1/PD-l1 checkpoint in bladder cancer: from mediator of immune escape to target for treatment. Urologicheskie vedomosti. 2018;8(2):64-72. (In Russ.)] https://doi.org/10.17816/uroved8264-72.
  51. Zhu HJ, Zhang ZQ, Zeng XF, et al. Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer. Cancer Gene Ther. 2004;11(4):263-272. https://doi.org/10.1038/sj.cgt.7700672.
  52. Zhang H, Wang F, Mao C, et al. Effect of combined treatment of radiation and tissue-specific recombinant oncolytic adenovirus on bladder cancer cells. Int J Radiat Biol. 2017;93(2):174-183. https://doi.org/10.1080/09553002.2017.1231942.
  53. Kotwal S, Choudhury A, Johnston C, et al. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. Int J Radiat Oncol Biol Phys. 2008;70(2):456-463. https://doi.org/10.1016/j.ijrobp.2007.06.030.
  54. Ploussard G, Daneshmand S, Efstathiou JA, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol. 2014;66(1):120-137. https://doi.org/10.1016/j.eururo.2014.02.038.
  55. Mathieu R, Lucca I, Klatte T, et al. Trimodal therapy for invasive bladder cancer: is it really equal to radical cystectomy? Curr Opin Urol. 2015;25(5):476-482. https://doi.org/10.1097/MOU.0000000000000203.
  56. Gerardi MA, Jereczek-Fossa BA, Zerini D, et al. Bladder preservation in non-metastatic muscle-invasive bladder cancer (MIBC): a single-institution experience. Ecancer medical science. 2016;10:657. https://doi.org/10.3332/ecancer.2016.657.
  57. Kulkarni GS, Hermanns T, Wei Y, et al. Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. J Clin Oncol. 2017;35(20):2299-2305. https://doi.org/10.1200/JCO.2016.69.2327.
  58. Rodel C, Weiss C. Organ-sparing multimodality treatment for muscle-invasive bladder cancer: can we continue to ignore the evidence? J Clin Oncol. 2014;32(34):3787-3788. https://doi.org/10.1200/JCO.2014.58.5521.
  59. Smith ZL, Christodouleas JP, Keefe SM, et al. Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy. BJU Int. 2013;112(1):13-25. https://doi.org/10.1111/j.1464-410X.2012.11762.x.
  60. Milowsky MI, Rumble RB, Booth CM, et al. Guideline on muscle-invasive and metastatic bladder cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2016;34(16):1945-1952. https://doi.org/10.1200/JCO.2015.65.9797.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать
2. Рис. 1. Общая выживаемость больных мышечно-инвазивным раком мочевого пузыря с учетом степени злокачественности опухоли [20]

Скачать (82KB)
Метаданные
3. Рис. 2. Общая выживаемость больных мышечно-инвазивным раком мочевого пузыря после органосохраняющего лечения [33]

Скачать (95KB)
Метаданные

© Старцев В.Ю., Дыленок И.Н., Джемилев Т.Р., 2019

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution 4.0 International License.
 


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах